SPOTLIGHT: Wyeth, Progenics drug gets fast-tracked

The intravenous form of methylnaltrexone has been granted Fast Track status by the FDA. Wyeth Pharmaceuticals Progenics Pharmaceuticals are investigating the drug for the treatment of postoperative ileus. Methylnaltrexone treats the side effects of opioid analgesics but does not interfere with pain relief. Release